The second part of the program will address the challenging circumstance of identifying novel approaches that can be used to enter the thriving immune-oncology space. The meeting will begin with a broad look at current understandings of the biology of immune-oncology and what has been learned from the many recent clinical studies in the space – and then explore specific opportunities related to new and underexplored targets, improvements in target selectivity and unmet medical needs. Special consideration will also be given to the translation of academic and clinical stage findings into commercial development programs. A discussion format will offer those in attendance a novel opportunity to explore strategies in this space with colleagues.

Preliminary Agenda


KEYNOTE PRESENTATION: Diverse Biologics Modalities Underpin ‘Third Wave’ Cancer Immunology Therapeutics

Jonathon Sedgwick, PhD, Global Head, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Emerging Technologies for Personalizing Cancer Immunotherapy

Aaron Goldman, PhD, Instructor in Medicine, Harvard Medical School


Microfluidic Single-Cell Technology in Immunology and Antibody Screening

Christoph Merten, PhD, Group Leader Microfluidics, European Molecular Biology Laboratory (EMBL), Germany

Antibody Discovery for Novel Multi-Targeting Strategy in Immuno-Oncology

Thomas Bouquin, PhD, Head, Biologics Research, Sanofi, France

Genome-Wide Networks of Stem Cell-Associated Retroviral Sequences Define Novel Diagnostic and Therapeutic Targets in Clinically Lethal Malignancies

Guennadi V. Glinskii, PhD, Research Scientist, Institute of Engineering in Medicine, University of California, San Diego


ErbB Targeted CAR-T Cell Immunotherapy of Head and Neck Cancer: T4 Immunotherapy

John Maher, PhD, Clinical Senior Lecturer in Immunology, Kings College London, United Kingdom

Development of DART® and TRIDENT™ Molecules to Target Costimulatory and Checkpoint Receptors for Immuno-Oncology Applications

Gundo Diedrich, PhD, Associate Director, MacroGenics

Converting PD-1 Refractory Tumors to Responders with Intratumoral Injection of a CpG-A TLR9 Agonist

Arthur M. Krieg, MD, CEO, Checkmate Pharmaceuticals

Peptide Based Checkpoint Inhibitor Binding to PD-1

Gabriel Gutierrez, PhD, Program Manager, Leidos Health

T-DM1-Resistant Cells Gain High Metastatic Potential: Identifying Novel Therapeutic Targets for the Treatment of T-DM1-Resistant Disease

Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA


Overcoming Specific Mechanisms of Resistance to Immuno-Oncology Therapies

Kris F. Sachsenmeier, PhD, Associate Director, Translational Sciences, AstraZeneca

Selection of Antibody-Drug Conjugate Targets Using Expression Data, Glycoproteomics, and Functional Screens

Jennifer J. Hill, PhD, Team Lead, MS & NMR Analytics, National Research Council Canada